Alexandre Bazinet, MD, and colleagues conducted the single-center, dose-expansion phase I/II trial... It led to an overall response rate of 74% in patients with newly diagnosed IDH2-mutated myelodysplastic syndrome. The researchers analyzed data from previously untreated adult patients with low- or intermediate-risk MDS. A retrospective study showed that response rate and survival outcome are still modest for high-risk patients.